<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR33">
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Zeuzem</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Arora</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Bacon</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Box</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Charlton</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Diago</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Dieterich</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Mur</surname>
    <given-names>RE</given-names>
   </name>
   <name>
    <surname>Everson</surname>
    <given-names>G</given-names>
   </name>
   <name>
    <surname>Fallon</surname>
    <given-names>M</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Pegylated interferon-Lambda (PEGIFN-lambda) shows superior viral response with improved safety and tolerability versus PEGIFN alpha-2A in HCV patients (G1/2/3/4): emerge phase IIB through week 12</article-title>
  <source>J Hepatol</source>
  <year>2011</year>
  <volume>54</volume>
  <fpage>S538</fpage>
  <lpage>S539</lpage>
  <pub-id pub-id-type="doi">10.1016/S0168-8278(11)61362-7</pub-id>
 </element-citation>
</ref>
